← All trials
NCT05125809
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Nov 18, 2021
- Last posted
- Nov 18, 2021
- Enrollment
- 195
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ultragenyx Inc.Lead sponsor
- Ultragenyx Inc.Study director
- Mereo BioPharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.